Navigation Links
Chiltern - Spectratox Drug Photoxicity Collaboration Celebrates 25 Years
Date:2/28/2011

LONDON, Feb. 28, 2011 /PRNewswire/ -- The staffs of Chiltern International Limited (Chiltern), a global contract research organization (CRO), and Spectratox Limited, celebrate the 25 year mark of their successful collaboration in Drug Phototoxicity.

Chiltern Early Phase and Spectratox have worked together using a validated and regulatory accepted in vivo human study method for the assessment of drug phototoxicity. The history of this collaboration can be traced through their multiple publications in peer reviewed journals.

"The success story of this methodology is not just measured in publications," stated Dr Brian Sanderson, Medical Director, Chiltern Early Phase. "It is measured in the success we have had in helping new drugs continue their developmental journey for areas of therapeutic need."

Professor James Ferguson, Head of the Academic Department of Dermatology, University of Dundee, and CEO of Spectratox, explained, "The evolution of randomized controlled trials has been in response to industry and regulatory requirements. Our trials, which tend to be conducted prior to Phase 3, produce data that defines the phototoxic risk in man in terms of severity and causal wavelengths as well as providing an understanding of the likelihood of ocular phototoxicity. Where phototoxicity is found, advice on protective measures to enable future development of the compound is an important aspect of our work."

Dr Sanderson added, "New study designs have been introduced to act as initial "screening" in man for drugs with potential phototoxicity. The new designs have evolved in response to the growing demand to assess this earlier in clinical drug development. The benefits are savings in both time and cost whilst remaining scientifically robust."

Glenn Kerkhof, Chiltern CEO, commented, "This 25 year collaboration is cause for celebration when we look back and realize the successes reached as well as what is presently being accomplished together. We very much look forward to what the next 25 years will bring in advancing drug development processes."

Company profilesAbout Chiltern:Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad range of therapeutic areas for a wide variety of clients. Chiltern has conducted trials in more than 40 countries, has 24 offices and legal entities within 20 countries, resources in 37 countries and employs nearly 1,400 people globally. Chiltern provides Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions services. Further information: www.chiltern.com.

About Spectratox:Spectratox, although formally established in 2008, came about from a group of staff within the Photobiology Unit who had been collaborating with the Chiltern staff on drug phototoxicity work in Scotland since the mid 1980s. Together they developed an evidence-based methodology for studying phototoxicity in clinical volunteers. Professor Ferguson has 30 years experience advising on the need for such work.  The staff at Spectratox are also expert in pre-clinical laboratory data analysis; clinical 'healthy volunteer' studies and post-study testing; advice on product labelling and clinical management.  

Phototoxicity testing is carried out on the premises of the National Photobiology Unit, Ninewells Hospital and Medical School, a part of NHS Tayside (although Spectratox Ltd. is an independent company).  Further information: www.spectratox.co.uk.For More Information Contact:Natalie Chong, Marketing Director

Susan Ojanen, Marketing AssociateChiltern International Ltd.

Chiltern International Inc.UNITED KINGDOM

USATel:  +44 (0) 1753 512 000

Tel:  +1 (423) 968 9533Email: natalie.chong@chiltern.com

Email: susan.ojanen@chiltern.com
'/>"/>

SOURCE Chiltern
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Chiltern Wins Multiple Pharma Awards at the Prestigious Annual PharmaTimes Awards Ceremony
2. Naviscan® Announces Collaboration With Neoprobe Corporation to Enable Pipeline Technology Development
3. Luminex and Partners HealthCare Announce Collaboration Agreement
4. Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
5. Endo Pharmaceuticals and Orion Corporation Begin Novel R&D Collaboration
6. Codexis Signs First Japanese Biocatalysis Collaboration With Dainippon Sumitomo Pharma
7. Ohio Business, Health Care Leaders Collaboration to Improve Patient Safety Results in Estimated Annual Savings of Nearly $13 Million
8. Collaborative Drug Discovery Receives New Funding to Support Tuberculosis Drug Discovery Screening Efforts and Industrial-Academic Collaborations
9. Ardea Biosciences Earns $15 Million Payment from Bayer HealthCare AG for Achievement of Important Clinical Milestone in Ongoing Collaboration
10. ImmunGene Announces Multi-Target R&D Collaboration With Cephalon Australia for Interferon Payload Technology
11. Veridex, LLC Announces Collaboration to Develop Next-Generation Circulating Tumor Cell (CTC) Technology with Massachusetts General Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , Jan 17, 2017 Research and Markets ... by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product ... Global Forecast to 2021" report to their offering. ... The global active pharmaceutical ... from USD 157.95 Billion in 2016, growing at a CAGR of ...
(Date:1/17/2017)... WARSAW, Ind. , Jan. 17, 2017  Zimmer ... leader in musculoskeletal healthcare , today announced ... capitalizes on the strength of the Zimmer Biomet ... D. Delp will assume the position of ... of the Company. Mr. Delp previously served as Zimmer ...
(Date:1/17/2017)... , Jan. 17, 2017 Tempus, ... cancer care, and University Hospitals Seidman Cancer Center ... by making genomic data, advanced molecular analysis and ... researchers, physicians and healthcare providers. ... provide genomic and transcriptomic sequencing and analysis for ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... ... the National Association of Music Merchants (NAMM) winter trade show, Booth #2876, at ... Etymotic’s ER•4® has long been the gold standard for high-definition, in-ear earphones. This ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... online continuing education for EMS and firefighting professionals, has released four new continuing ... These new courses are taught live in an online classroom and meet the ...
(Date:1/17/2017)... ... January 17, 2017 , ... SensorInsight ®, an Internet ... in the U.S.A. to offer Internet of Things (IoT) solutions based on ... sensor deployments such as monitoring solutions used to detect potentially hazardous conditions in ...
(Date:1/17/2017)... , ... January 17, 2017 , ... Livionex, Inc., a ... of a double blind clinical study for its dental gel that shows significant reduction ... brand of toothpaste containing triclosan. The study was conducted at the Beckman Laser Institute ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... ranked among the top US security companies for consecutive years, today announced the ... brings a year-long independent board nomination process to a close and positions Lynx ...
Breaking Medicine News(10 mins):